Quick Answer
CRISPR Therapeutics AG reported Research And Development Expense of $284.81 million for the year ending 2025.
- CRISPR Therapeutics AG showed a decrease of -8.2% in Research And Development Expense from 2024 to 2025.
- This data is from CRISPR Therapeutics AG's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), CRISPR Therapeutics AG's Research And Development Expense has grown by 18,723.9%.
- Historical annual values: Fiscal year 2025: $284.81 million | Fiscal year 2024: $310.24 million | Fiscal year 2023: $387.33 million | Fiscal year 2022: $461.65 million | Fiscal year 2021: $340.57 million | Fiscal year 2020: $221.38 million | Fiscal year 2019: $179.36 million | Fiscal year 2018: $113.77 million | Fiscal year 2017: $69.80 million | Fiscal year 2016: $42.24 million | Fiscal year 2015: $12.57 million | Fiscal year 2014: $1.51 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: